MSB 3.46% 97.3¢ mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-272

  1. 2,678 Posts.
    lightbulb Created with Sketch. 1724

    excerpt from attached .

    The provision refers to proposed product labeling rather than the suggested final printed labeling because we generally review the latter only after an applicant has addressed
    any major deficiencies in an application.

    Dear Phaedrus,
    It appears if the data for the potency assay measures up then we still need to endure final printed labelling approval. Perhaps " stick it in sore spot" will suffice .
    Some light reading for your enjoyment attached.


    My take is we will get an announcement in about 9 trading days stating the potency assay has been accepted/agreed to and approved. But this will not be a full approval/ nor accelerated as
    labelling still to tick off. If I'm right , do you ( someone ) have any idea how long that will take? Two weeks ?

    Reg

    https://www.federalregister.gov/documents/2008/07/10/E8-15608/applications-for-approval-to-market-a-new-drug-complete-response-letter-amendments-to-unapproved
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.3¢
Change
0.033(3.46%)
Mkt cap ! $1.110B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $2.389M 2.497M

Buyers (Bids)

No. Vol. Price($)
29 113063 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 91679 18
View Market Depth
Last trade - 13.46pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.